LIPO-5Other Names: ANRS HIV-LIPO-5, HIV-LIPO-5 Drug Class: Therapeutic Vaccines Organization: French National Agency for Research on AIDS and Viral Hepatitis (ANRS) Phase of Development: LIPO-5 is in Phase II development as a therapeutic HIV vaccine. (LIPO-5 is also being studied as a preventive HIV vaccine.)
(Compound details obtained from ANRS: HIV Vaccine Research Programme,1 AIDS article,2 and Treatment Action Group website3)
What is LIPO-5?
LIPO-5 is an investigationalthat is being studied as a possible strategy to treat people living with HIV.3 LIPO-5 belongs to a group of HIV vaccines called therapeutic HIV vaccines.
How do therapeutic HIV vaccines work?
A What is a Therapeutic HIV Vaccine? fact sheet.is a type of vaccine that’s designed to improve the body’s to HIV in a person living with HIV.4 Therapeutic vaccines work by strengthening the to recognize and eliminate HIV from the body. To learn more, read the
There are several types of therapeutic vaccines currently being studied to treat HIV. Besides being studied as a therapeutic HIV vaccine, researchers are also investigating the LIPO-5 vaccine to see if it can prevent HIVin people who do not have the .1,2,5 This vaccine record focuses on the study of LIPO-5 as a therapeutic vaccine.
Which clinical trials are studying LIPO-5?
LIPO-5 therapeutic HIV vaccine
Study Names: VRI02/ANRS 149 LIGHT; NCT01492985
Status: This study is ongoing, but not recruiting participants.
Purpose: The purpose of this study is to find out whether a combination of the DNA vaccine GTU-MultiHIV B and LIPO-5 can produce an immune response in the body that controls levels after a treatment interruption.6
For more details on this study, see the Health Professional version of this drug summary.
What side effects might LIPO-5 cause?
One goal of HIV research is to identify new drugs that have fewer side effects. In the VRI02/ANRS 149 LIGHT study (NCT01492985), participants received either GTU-MultiHIV B and LIPO-5 vaccines or vaccines. Of the participants who received at least one vaccine injection, most of the reported side effects were mild. One participant developed arthritis, which was possibly related to (either study vaccine or placebo). Among participants who underwent a treatment interruption, all experienced . Some participants had symptoms resembling after undergoing a treatment interruption, though reported symptoms were mostly mild. One participant transmitted HIV infection during the period of treatment interruption.6,7
Because LIPO-5 is still being studied, information on possible side effects of the vaccine is not complete. As testing of LIPO-5 continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying LIPO-5?
More information about LIPO-5-related research studies is available from ClinicalTrials.gov.
- ANRS HIV Vaccine Network. ANRS: HIV vaccine research programme. http://www.anrs.fr/content/download/1539/10054/file/hiv. Published December 2010. Accessed October 17, 2016.
- Salmon-Céron D, Durier C, Desaint C, et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS. 2010;24(14):2211-2223.
- Treatment Action Group website. Research toward a cure trials. http://www.treatmentactiongroup.org/cure/trials. Accessed February 6, 2019.
- The History of Vaccines website. The development of HIV vaccines. https://www.historyofvaccines.org/content/articles/development-hiv-vaccines. Accessed February 6, 2019.
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Phase I/II open-label randomized multicenter trial to assess immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in healthy volunteers at low risk of HIV infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 2, 2014. NLM Identifier: NCT02038842. https://clinicaltrials.gov/ct2/show/NCT02038842. Accessed February 6, 2019.
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Evaluation of a therapeutic immunization strategy associating a DNA vaccine (GTU-MultiHIV B) followed by a lipopeptide vaccine (LIPO-5) in the control of viral replication following antiretroviral treatment interruption in HIV-1 infected patients with a CD4 cell count ≥ 600/mm3. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 24, 2011. NLM Identifier: NCT01492985. https://clinicaltrials.gov/ct2/show/NCT01492985. Accessed February 6, 2019.
- Levy Y, Lelievre J-D, Perrier A, et al. Preliminary safety results from VRI02 ANRS 149 Light (lipopeptide and DNA GTU HIV therapeutic trial). Poster presented at: HIV Research for Prevention (HIVR4P); October 17-21, 2016; Chicago, IL. Poster P27.09. https://www.abstractstosubmit.com/hivr4p2016/eposter/main.php?do=YToyOntzOjU6Im1vZHVsIjtzOjY6ImRldGFpbCI7czo4OiJkb2N1bWVudCI7aTo3NTt9&. Accessed February 6, 2019.
Last Reviewed: February 6, 2019
- Patient Version HTML